TriLink BioTechnologies社 January TriLink Messenger
| この製品に関するご意見・ご照会・お問合せはこちら |
 |
 |
|
Research News
mRNA Therapeutic for Treatment of Argininosuccinic Aciduria, an Inherited Rare Metabolic Disorder
Exploring groundbreaking advancements in treating Argininosuccinic aciduria (ASA), a rare metabolic disorder, this article highlights a collaborative effort by BioNTech SE and Genevant Sciences, including a 2023 Nobel laureate Katalin Karikó. The research delves into lipid nanoparticle-formulated mRNA therapies, showcasing promising results in enhancing safety, efficacy, and survival rates in mouse models, offering a potential breakthrough in ASA treatment.
|
 |
 |
|
A novel mRNA delivery system offers organ-specific targeting
Learn how Stanford University researchers used TriLink’s mRNAs, which are capped with a CleanCap® analog and modified with 5-methoxyuridine, to develop an mRNA delivery system for improved transfection of primary T lymphocytes in vitro and highly selective organ tropism in vivo.
|
Advances in mRNA nanotherapy
A new Nano Today review reports key milestones in mRNA nanotherapy, including the development of TriLink’s CleanCap® technology, which was used to cap the Pfizer/BioNTech COVID-19 vaccine. Learn how TriLink’s CleanCap® technology is advancing the development of mRNA nanotherapies.
|
Get all your questions answered in our CleanCap® video series
|
 |
 |
 |
|
mRNA caps and CleanCap® technology
Learn about mRNA capping, differences in the mRNA capping methods, and how CleanCap® technology can accelerate the development of your mRNA, cell, and gene therapies.
|
Benefits of CleanCap® technology
Hear how CleanCap® technology streamlines the mRNA capping process and how TriLink BioTechnologies is working on innovations for cap analogs.
|
Innovations in CleanCap® technology
TriLink BioTechnologies is committed to innovating better versions of CleanCap® cap analogs to help our partners come up with better vaccines and treatments.
|
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
